Relevant bibliographies by topics / RASSI / Journal articles
To see the other types of publications on this topic, follow the link: RASSI.

Journal articles on the topic 'RASSI'

Author: Grafiati
Published: 11 September 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'RASSI.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Rassi, Anis, and Anis Rassi. "Rassi Score." Journal of the American College of Cardiology 73, no. 13 (April 2019): 1734–35. http://dx.doi.org/10.1016/j.jacc.2018.12.079.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Van den Heuvel, Willem, Simone Calvello, and Alessandro Soncini. "Configuration-averaged 4f orbitals in ab initio calculations of low-lying crystal field levels in lanthanide(iii) complexes." Physical Chemistry Chemical Physics 18, no. 23 (2016): 15807–14. http://dx.doi.org/10.1039/c6cp02325h.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Maity, Souvik, Arpan Mondal, Sanjit Konar, and Ashutosh Ghosh. "The role of 3d–4f exchange interaction in SMM behaviour and magnetic refrigeration of carbonato bridged CuII2LnIII2 (Ln = Dy, Tb and Gd) complexes of an unsymmetrical N2O4 donor ligand." Dalton Transactions 48, no. 40 (2019): 15170–83. http://dx.doi.org/10.1039/c9dt02627d.

Full text
Abstract:
The role of exchange interaction between Cu(ii) and Ln(iii) ions in SMM behaviour and magnetocaloric effects has been extensively investigated by both experimental and theoretical CASSCF/RASSI-SO/SINGLE_ANISO methods.
APA, Harvard, Vancouver, ISO, and other styles
4

KAWARADA, SHUMPEI, HISASHI IMAMURA, YOJI NARIMATSU, and GENTO SHINOHARA. "Taxonomic revision of the genus Lycenchelys (Osteichthyes: Zoarcidae) in Japanese waters." Zootaxa 4762, no. 1 (April 7, 2020): 1–66. http://dx.doi.org/10.11646/zootaxa.4762.1.1.

Full text
Abstract:
Eelpout species of the genus Lycenchelys Gill, 1884 recorded from Japanese waters are taxonomically revised. This study recognizes the following 11 species from Japanese waters as valid: Lycenchelys albomaculata Toyoshima, 1983, Lycenchelys aurantiaca Shinohara & Matsuura, 1998, Lycenchelys hippopotamus Schmidt, 1950, Lycenchelys maculata Toyoshima, 1985, Lycenchelys makushok Fedorov & Andriashev, 1993, Lycenchelys melanostomias Toyoshima, 1983, Lycenchelys rassi Andriashev, 1955, Lycenchelys remissaria Fedorov, 1995, Lycenchelys ryukyuensis Shinohara & Anderson, 2007, Lycenchelys squamosa Toyoshima, 1983 and Lycenchelys tohokuensis Anderson & Imamura, 2002. We redescribe species in detail based on type specimens as well as additional specimens in many cases. The synonymy of Lycenchelys brevimaxillaris Toyoshima, 1985 with L. melanostomias is supported in this study. Sexual dimorphism and changes with growth are revealed in L. albomaculata, L. aurantiaca, L. hippopotamus, L. makushok, L. melanostomias and L. rassi, all based on 10 or more specimens, for relative head length, head width, and upper and lower jaw lengths. In addition, we also found that the sizes at which sexual dimorphism can be recognized, and the tendencies for change with growth, differ among species. Furthermore, the dimorphism in head length is influenced by the snout length, eye diameter and/or postorbital length in L. albomaculata and L. aurantiaca.
APA, Harvard, Vancouver, ISO, and other styles
5

Trenker, Martin. "Der vom Berufungsgericht verneinte Verfahrensmangel erster Instanz als tauglicher Revisionsgrund – Duplik zu Rassi." Juristische Blätter 143, no. 9 (2021): 614. http://dx.doi.org/10.33196/jbl202109061401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Malmqvist, Per-Åke. "The RASSCF, RASSI, and CASPT2 Methods Used on Small Molecules of Astrophysical Interest." International Astronomical Union Colloquium 146 (1994): 338–52. http://dx.doi.org/10.1017/s0252921100021448.

Full text
Abstract:
To a quantum chemist with no particular background in astrophysics or astronomy, a brief glance at journals and textbooks in these fields shows at least three areas where computational quantum chemistry has had a valuable impact: Interstellar cloud chemistry; stellar atmosphere modelling; and chemistry in extreme conditions, such as at the surface of a neutron star. The first two uses are particularly suitable, since standard methods are directly applicable.For such problems, good calculations of potential energy as well as expectation values and matrix elements of dipole and other operators appears to be in demand. Many electronic states may be involved, at least a broad range of problems involve fairly small molecules, often radicals, and conformation regions far from equilibrium. Such problems are addressed by three methods originated in our laboratory, and known by the acronyms RASSCF (Restricted Active Space Self-Consistent Field, Malmqvist et al. 1990), RASSI (RAS State Interaction) and CASPT2 (Complete Active Space Perturbation Theory to Second Order-Complete Active Space Perturbation Theory to Second Order, Andersson et al. 1990; Andersson et al. 1992).
APA, Harvard, Vancouver, ISO, and other styles
7

Magni, Fulvio, and Cecilia Sarto. "Book Review: Carbohydrate analysis by modern chromatography and electrophoresis. By Ziad El Rassi." PROTEOMICS 3, no. 6 (June 2003): 1086–87. http://dx.doi.org/10.1002/pmic.200390080.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Merejo Peña, Catherine Masiel, Michel Silva Reis, Basílio de Bragança Pereira, Emília Matos do Nascimento, and Roberto Coury Pedrosa. "Dysautonomy in different death risk groups (Rassi score) in patients with Chagas heart disease." Pacing and Clinical Electrophysiology 41, no. 3 (January 30, 2018): 238–45. http://dx.doi.org/10.1111/pace.13270.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ivanov, A. S., X. Zhang, H. Wang, A. I. Boldyrev, G. Gantefoer, K. H. Bowen, and I. Černušák. "Anion Photoelectron Spectroscopy and CASSCF/CASPT2/RASSI Study of Lan– (n = 1, 3–7)." Journal of Physical Chemistry A 119, no. 46 (November 6, 2015): 11293–303. http://dx.doi.org/10.1021/acs.jpca.5b08076.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ren, Chi, Weiming Liu, Xue Yin, Bingyu Zhang, and Peirong Lu. "Renin-Angiotensin System Inhibitor Usage and Age-Related Macular Degeneration among Hypertensive Patients: Results from the National Health and Nutrition Examination Survey, 2005–2008." Journal of Ophthalmology 2020 (June 24, 2020): 1–8. http://dx.doi.org/10.1155/2020/4252031.

Full text
Abstract:
Purpose. To assess whether renin-angiotensin system inhibitor (RASI) utilization is associated with age-related macular degeneration (AMD) prevalence among hypertensive patients. Methods. A US population-based, cross-sectional study was conducted. 3,023 hypertensive participants aged 40 years and older with gradable retinal images and ascertained RASI usage in the National Health and Nutrition Examination Survey (NHANES), 2005–2008, were finally enrolled into the study. RASI usage was obtained by interview, and AMD was determined through retinal image assessment. We performed multivariable analyses to assess the relationship between utilization of RASIs and AMD prevalence. We also took drug treatment duration into account, in order to better understand the effects of RASIs. Results. Multivariable logistic regression analyses revealed that AMD prevalence had no significant association with RASI usage but was inversely correlated with RASI treatment duration (odds ratio (OR) = 0.87, 95% confidence interval (CI) = 0.78–0.98, p=0.02). Long-term usage (>5 years) of RASIs was significantly associated with not only reduced overall risk of AMD (OR = 0.23, 95% CI = 0.14–0.38, p<0.001) but also lower propensity to have early (OR = 0.23, 95% CI = 0.14–0.37, p<0.001) and late (OR = 0.25, 95% CI = 0.07–0.87, p=0.03) AMD. Furthermore, long-term RASI users were less prone to develop soft drusen (OR = 0.67, 95% CI = 0.45–0.99, p=0.04) and geographic atrophy (GA) (OR = 0.39, 95% CI = 0.22–0.71, p=0.003). Conclusions. Evidence supporting that RASI utilization could directly protect against AMD in hypertensive patients was still insufficient, but long-term RASI treatment seemed to be beneficial for both early and late AMD, implicating a promising therapeutic approach that RASIs might offer for AMD prevention and management.
APA, Harvard, Vancouver, ISO, and other styles
11

Kai, Hisashi, Mamiko Kai, Hiroshi Niiyama, Norihito Okina, Motoki Sasaki, Takanobu Maeda, and Atsushi Katoh. "Overexpression of angiotensin-converting enzyme 2 by renin-angiotensin system inhibitors. Truth or myth? A systematic review of animal studies." Hypertension Research 44, no. 8 (March 10, 2021): 955–68. http://dx.doi.org/10.1038/s41440-021-00641-1.

Full text
Abstract:
AbstractAngiotensin-converting enzyme 2 (ACE2) protects against organ damage in hypertension and cardiovascular diseases by counter regulating the renin-angiotensin system (RAS). ACE2 is also the receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Based on the claim that RAS inhibitors (RASIs) cause ACE2 overexpression in some animal experiments, concerns have arisen that RASIs may aggravate SARS-CoV-2 infection and coronavirus disease-2019 severity in RASI-treated patients. To achieve a comprehensive review, a systematic search of MEDLINE/PubMed was conducted regarding the effects of RASIs on tissue ACE2 mRNA/protein expression in healthy animals and animal models of human diseases. We identified 88 eligible articles involving 168 experiments in the heart, kidneys, lungs, and other organs. Three of 38 experiments involving healthy animals showed ACE2 expression greater than twice that of the control (overexpression). Among 102 disease models (130 experiments), baseline ACE2 was overexpressed in 16 models (18 experiments) and less than half the control level (repression) in 28 models (40 experiments). In 72 experiments, RASIs did not change ACE2 levels from the baseline levels of disease models. RASIs caused ACE2 overexpression compared to control levels in seven experiments, some of which were unsupported by other experiments under similar conditions. In 36 experiments, RASIs reversed or prevented disease-induced ACE2 repression, yielding no or marginal changes. Therefore, ACE2 overexpression appears to be a rare rather than common consequence of RASI treatment in healthy animals and disease models. Future studies should clarify the pathophysiological significance of RASI-induced reversal or prevention of ACE2 repression in disease models.
APA, Harvard, Vancouver, ISO, and other styles
12

Reis, Sonia, and Jorge Baptista. "Descrição e classificação sintática das expressões proverbiais do Português Europeu." Diacrítica 33, no. 2 (December 16, 2019): 324–34. http://dx.doi.org/10.21814/diacritica.412.

Full text
Abstract:
Os provérbios são expressões de uso generalizado, utilizados em diferentes situações conversacionais e assumindo diferentes funções no discurso em que se integram. Do ponto de vista sintático, este tipo de expressões apresenta uma grande variedade de estruturas. Tendo isto em conta, o objetivo principal deste trabalho é estabelecer uma classificação formal sintática dos provérbios do português europeu. Para tal, pretendemos desenvolver e aprofundar a tipologia de classificação formal proposta por Rassi et al. (2014). Por conseguinte, será considerada uma subclassificação para as classes que apresentam um elevado número de provérbios e uma eventual reclassificação de alguns dos tipos. Esta classificação, por sua vez, será o ponto de partida para o desenvolvimento de um procedimento de classificação automática deste tipo de estruturas, e contribuir assim para a elaboração de recursos para diferentes aplicações em Processamento da Linguagem Natural (PLN).
APA, Harvard, Vancouver, ISO, and other styles
13

Bimpong, Isaac Kofi, Baboucarr Manneh, Mamadou Sock, Faty Diaw, Nana Kofi Abaka Amoah, Abdelbagi M. Ismail, Glenn Gregorio, Rakesh Kumar Singh, and Marco Wopereis. "Improving salt tolerance of lowland rice cultivar ‘Rassi’ through marker-aided backcross breeding in West Africa." Plant Science 242 (January 2016): 288–99. http://dx.doi.org/10.1016/j.plantsci.2015.09.020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Moriyama, Shohei, Michinari Hieda, Megumi Kisanuki, Shotaro Kawano, Taku Yokoyama, Mitsuhiro Fukata, Hitoshi Kusaba, et al. "Effect of renin–angiotensin system inhibitors in patients with cancer treated with anti-VEGF therapy." Open Heart 9, no. 2 (December 2022): e002135. http://dx.doi.org/10.1136/openhrt-2022-002135.

Full text
Abstract:
BackgroundCancer treatment with vascular endothelial growth factor signalling pathway (VSP) inhibitors frequently causes hypertension. Although previous reports suggested that the antihypertensive drug renin–angiotensin system inhibitor (RASI) may have a positive synergistic effect with VSP inhibitors, the actual impact on clinical outcomes is unknown.ObjectivesThe study aims to clarify whether RASIs exhibit clinical benefits for patients with cancer with hypertension.MethodFrom the Longevity Improvement and Fair Evidence Study database, comprising Japanese claims data between 2016 and 2020, we reviewed 2380 patients treated with VSP inhibitors who received antihypertensive treatment during cancer therapy. The patients were classified into two groups: with-RASI (n=883) and without-RASI (n=1497). In addition, 1803 of these patients treated for hypertension with RASI-only (n=707) or calcium channel blocker-only (n=1096) were also reviewed. The time-to-treatment failure (TTF), the interval from initiation of chemotherapy to its discontinuation, was applied as the primary endpoint.ResultsThe median TTFs were 167 (60–382) days in the with-RASI group and 161 (63–377) days in the without-RASI group (p=0.587). All models, including Cox proportional hazard models and multiple propensity score models, did not reveal the superiority of with-RASI treatment. In the propensity score matching model, the HR for treatment with-RASI compared with that for without-RASI was 0.96 (95% CI 0.86 to 1.06, p=0.386). In addition, the TTFs of RASI-only were not superior to calcium channel blocker-only (p=0.584).ConclusionsRASIs for hypertension do not benefit clinical outcomes during cancer therapy with VSP inhibitors. In addition, RASIs and calcium channel blockers have comparable clinical efficacy as first-line antihypertensive.
APA, Harvard, Vancouver, ISO, and other styles
15

Keegan, Roberto, Cynthia Yeung, and Adrian Baranchuk. "Sudden Cardiac Death Risk Stratification and Prevention in Chagas Disease: A Non-systematic Review of the Literature." Arrhythmia & Electrophysiology Review 9, no. 4 (December 24, 2020): 175–81. http://dx.doi.org/10.15420/aer.2020.27.

Full text
Abstract:
Chagas disease is an important public health problem in Latin America. However, migration and globalisation have resulted in the increased presence of Chagas disease worldwide. Sudden cardiac death is the leading cause of death in people with Chagas disease, most often due to ventricular fibrillation. Although more common in patients with documented ventricular arrhythmias, sudden cardiac death can also be the first manifestation of Chagas disease in patients with no previous symptoms or known heart failure. Major predictors of sudden cardiac death include cardiac arrest, sustained and non-sustained ventricular tachycardia, left ventricular dysfunction, syncope and bradycardia. The authors review the predictors and risk stratification score developed by Rassi et al. for death in Chagas heart disease. They also discuss the evidence for anti-arrhythmic drugs, catheter ablation, ICDs and pacemakers for the prevention of sudden cardiac death in these patients. Given the widespread global burden, understanding the risk stratification and prevention of sudden cardiac death in Chagas disease is of timely concern.
APA, Harvard, Vancouver, ISO, and other styles
16

Lin, Jing, Liu He, Qing Qiao, Xin Du, Chang-Sheng Ma, and Jian-Zeng Dong. "Renin–angiotensin system inhibitors and clinical outcomes in patients with atrial fibrillation and heart failure: a propensity score-matched study from the Chinese Atrial Fibrillation Registry." Journal of International Medical Research 49, no. 9 (September 2021): 030006052110414. http://dx.doi.org/10.1177/03000605211041439.

Full text
Abstract:
Objective The effect of renin–angiotensin system inhibitors (RASIs) in patients with heart failure (HF) and atrial fibrillation (AF) remains unclear. This study aimed to investigate associations between RASI use and all-cause mortality and cardiovascular outcomes in patients with AF and HF. Methods Using data from the China Atrial Fibrillation Registry study, we included 938 patients with AF and HF with a left ventricular ejection fraction <50%. Cox regression models for RASIs vs. non-RASIs with all-cause mortality as the primary outcome were fitted in a 1:1 propensity score-matched cohort. A sensitivity analysis was performed by using a multivariable time-dependent Cox regression model. As an internal control, we assessed the relation between β-blocker use and all-cause mortality. Results During a mean follow-up of 35 months, the risk of all-cause mortality was similar in RASI users compared with non-users (hazard ratio: 0.92; 95% confidence interval: 0.67–1.26). Similar results were obtained in the sensitivity analysis. In contrast, β-blocker use was associated with significantly lower all-cause mortality in the same population. Conclusions RASI use was not associated with better outcomes in patients with AF and HF in this prospective cohort, which raises questions about their value in this specific subset. Trail Registration: ChiCTR-OCH-13003729.
APA, Harvard, Vancouver, ISO, and other styles
17

Shmelev, Maxim A., Ruslan A. Polunin, Natalia V. Gogoleva, Igor S. Evstifeev, Pavel N. Vasilyev, Alexey A. Dmitriev, Evgenia A. Varaksina, et al. "Cadmium-Inspired Self-Polymerization of {LnIIICd2} Units: Structure, Magnetic and Photoluminescent Properties of Novel Trimethylacetate 1D-Polymers (Ln = Sm, Eu, Tb, Dy, Ho, Er, Yb)." Molecules 26, no. 14 (July 15, 2021): 4296. http://dx.doi.org/10.3390/molecules26144296.

Full text
Abstract:
A series of heterometallic carboxylate 1D polymers of the general formula [LnIIICd2(piv)7(H2O)2]n·nMeCN (LnIII = Sm (1), Eu (2), Tb (3), Dy (4), Ho (5), Er (6), Yb (7); piv = anion of trimethylacetic acid) was synthesized and structurally characterized. The use of CdII instead of ZnII under similar synthetic conditions resulted in the formation of 1D polymers, in contrast to molecular trinuclear complexes with LnIIIZn2 cores. All complexes 1–7 are isostructural. The luminescent emission and excitation spectra for 2–4 have been studied, the luminescence decay kinetics for 2 and 3 was measured. Magnetic properties of the complexes 3–5 and 7 have been studied; 4 and 7 exhibited the properties of field-induced single-molecule magnets in an applied external magnetic field. Magnetic properties of 4 and 7 were modelled using results of SA-CASSCF/SO-RASSI calculations and SINGLE_ANISO procedure. Based on the analysis of the magnetization relaxation and the results of ab initio calculations, it was found that relaxation in 4 predominantly occurred by the sum of the Raman and QTM mechanisms, and by the sum of the direct and Raman mechanisms in the case of 7.
APA, Harvard, Vancouver, ISO, and other styles
18

OLIVEIRA, Júlia De Cássia, Sara Alves dos Santos TAQUARY, Aurélio De Melo BARBOSA, and Rafaela Júlia Batista VERONEZI. "PÉ DIABÉTICO: PERFIL SOCIODEMOGRÁFICO E CLÍNICO DE PACIENTES HOSPITALIZADOS." Revista Brasileira de Ciências da Saúde 22, no. 1 (March 6, 2018): 15–20. http://dx.doi.org/10.22478/ufpb.2317-6032.2018v22n1.23034.

Full text
Abstract:
Introdução: O pé diabético é uma das complicações ocasionadas pelo diabetes. É definido como um quadro de infecção, ulceração e/ou destruição dos tecidos profundos associados à neuropatia com ou sem coexistência de doença vascular periférica. Objetivo: Apresentar o perfil sociodemográfico e clínico dos pacientes internados para tratamento de pé diabético. Materiais e Métodos: Um estudo transversal foi feito entre janeiro e junho de 2014 no Hospital Alberto Rassi (HGG), em Goiânia, Goiás. Foram entrevistados os pacientes internados por pé diabético, com a utilização de um formulário de dados. Resultados: A amostra foi composta por 42 pessoas, sem predomínio de sexo. A média de idade foi de 62,1 anos, com predomínio do estado civil casado (66,7%) e aposentado (52,4%). No histórico familiar, 76,2% da amostra possuía diabetes e 78,6% hipertensão arterial. Esta foi a comorbidade mais presente nos indivíduos. As complicações provenientes do diabetes predominantes foram neuropatia (69,0%) e vasculopatia (64,3%). A causa da lesão foi principalmente não traumática (52,4%), sendo que prevaleceram as úlceras sem infecção associada (59,5%). Quanto à classificação de Wagner, o grau 4 representou 61,9% das lesões. Conclusão: As feridas nos pés foram graves, com longo tempo de evolução, evidenciando a necessidade de educação em saúde com enfoque na prevenção e no autocuidado. DESCRITORES: Pé diabético. Hospitalização. Estudos Transversais.
APA, Harvard, Vancouver, ISO, and other styles
19

Devarajan, Ajitha, Alexander Gaenko, Roland Lindh, and Per-Åke Malmqvist. "Role of electronic curve crossing of benzeneS1state in the photodissociation of aryl halides, effect of fluorination: RASSI-SO MS-CASPT2 study." International Journal of Quantum Chemistry 109, no. 9 (2009): 1962–74. http://dx.doi.org/10.1002/qua.22033.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

NIELSEN, JØRGEN G., JOHN J. POGONOSKI, and SHARON A. APPLEYARD. "Aphyonid-clade species of Australia (Teleostei, Bythitidae) with four species new to Australian waters and a new species of Barathronus." Zootaxa 4564, no. 2 (March 6, 2019): 554. http://dx.doi.org/10.11646/zootaxa.4564.2.12.

Full text
Abstract:
During voyages in 2017 off southern and southeastern Australia, the Australian Research Vessel Investigator deployed a series of demersal beam trawls to depths of around 5000 metres. Nineteen specimens of the rarely caught aphyonid-clade of the ophidiiform family Bythitidae, representing five species, were caught. Four of these are new to Australian waters: Barathronus pacificus Nielsen and Eagle, 1974 known from the northeastern and southwestern Pacific Ocean, Paraphyonus bolini (Nielsen, 1974) known from the western Indian and western Pacific Oceans, Paraphyonus rassi (Nielsen, 1975) known from the Atlantic Ocean and Sciadonus pedicellaris Garman, 1899, known from the northeastern Atlantic and northeastern and southwestern Pacific Oceans. Also included are Aphyonus gelatinosus Günther, 1878 known from all oceans including ten specimens from Australian waters, Barathronus maculatus Shcherbachev, 1976 known from South Africa to the westernmost Pacific including 13 specimens from Australian waters, Sciadonus longiventralis Nielsen, 2018 known from the holotype collected off New South Wales and finally Barathronus algrahami n. sp. known from the holotype caught off South Australia and four paratypes from off Taiwan and northern Philippines. Close examination of specimens collected during recent voyages combined with recent and ongoing studies by the first author and DNA COI barcoding analysis enabled an assessment of the aphyonid-clade species hitherto recorded from Australian waters. An identification key to the eight aphyonid clade species known from Australian waters is provided.
APA, Harvard, Vancouver, ISO, and other styles
21

Choi, In Suck, Ie Byung Park, Kiyoung Lee, Tae Hoon Ahn, Ju Han Kim, Youngkeun Ahn, Sung-Chull Chae, et al. "Angiotensin-Converting Enzyme Inhibitors Provide Better Long-Term Survival Benefits to Patients With AMI Than Angiotensin II Receptor Blockers After Survival Hospital Discharge." Journal of Cardiovascular Pharmacology and Therapeutics 24, no. 2 (August 21, 2018): 120–29. http://dx.doi.org/10.1177/1074248418795897.

Full text
Abstract:
Aim: Renin–angiotensin–aldosterone system inhibitors (RASIs) are widely used in high-risk cardiovascular (CV) diseases, including acute myocardial infarction (AMI). However, it is not yet clear which class of RASIs provides specific benefits to patients with AMI. The present study aimed to evaluate whether angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs) had any different effects on long-term CV and all-cause mortality in patients with AMI who received either agent from admission and were discharged alive from the hospital. Methods: We analyzed data of patients with AMI from the Korea Acute Myocardial Infarction Registry-National Institutes of Health registry. Cardiovascular and all-cause mortality at 12 months after AMI were assessed. Results: Among 12 481 patients with AMI who were discharged alive, RASI treatment was as follows: ACEIs (n = 5910), ARBs (n = 4009), and no RASI (n = 2562). After adjustment for multiple factors, compared with no RASI therapy, ACEI therapy was associated with lower hazard ratios (HRs) for 1-year CV and total mortality rates, whereas ARB therapy was not. In a direct comparison, compared with ARB treatment, ACEI treatment was associated with lower HRs (95% confidence interval) for CV and total mortality: 0.562 (0.420-0.753) and 0.567 (0.451-0.713), respectively. The superiority of ACEI to ARB was also observed across several subgroups. The mortality differences between the 2 treatment groups were reproduced in a propensity-score matched analysis (n = 2855 each). Conclusions: Our study of a recent AMI registry data revealed that ACEI therapy in patients with AMI was associated with better long-term survival benefits than ARB therapy.
APA, Harvard, Vancouver, ISO, and other styles
22

Bangale, Jaya, and Surekha Devkate. "Involvement of Rural Children in Recreational Play Activities and their views about it." International Journal of Current Microbiology and Applied Sciences 11, no. 4 (April 10, 2022): 165–73. http://dx.doi.org/10.20546/ijcmas.2022.1104.023.

Full text
Abstract:
One hundred and fifty rural children (76 female and 74 Male) in the age range of 9 – 12 yrs were chosen at random from 5 villages of Parbhani District (MS) for studying involvement of rural children in recreational play activities and their views about it. The data related to the study were collected by personally interviewing of rural children based on structured and open ended interview schedule. It is obvious from the results that irrespective of gender higher percentage (54-86%) of rural children were observed to be involved in various outdoor play such as Lagori (86.66%) followed by Hide and Seek (85.33%),Chain game (84.00%), Running (83.33%), Kho-kho (80.66%), Chor Shipai (75.33%), Rassi khech (74.00%), Langadi (62), Kabbadi (68.66%), Blind fold (54.00%) for recreation purpose. Further it was observed that sample rural children sometimes used to play indoor play such as Stone games/ Sagargote (60.65%), Five corners (57.89%), Chimani udali bhoor (54.61%) and Bhatukali (47.72%) for recreation purpose. It was recorded that girls are getting less leisure time as compare to boys to involve in recreational activities. With regard to the benefits of involving in recreational activities, all the rural school going children expressed that they experienced sense of joy followed by having improvement in their health status(93.33%), enhanced physical fitness (88.66%), raised status in friends circle (83.33%), improved communication skills (79.33%). children expressed that their involvement in various recreational activities is sometimes become a cause for their parental aggression due to their participation in recreational play activities.
APA, Harvard, Vancouver, ISO, and other styles
23

Qin, Xiwen, Joseph Hung, Tiew-Hwa Katherine Teng, Tom Briffa, and Frank M. Sanfilippo. "Long-Term Adherence to Renin–Angiotensin System Inhibitors and β-Blockers After Heart Failure Hospitalization in Senior Patients." Journal of Cardiovascular Pharmacology and Therapeutics 25, no. 6 (June 5, 2020): 531–40. http://dx.doi.org/10.1177/1074248420931617.

Full text
Abstract:
Aims: We investigated long-term adherence to renin–angiotensin system inhibitors (RASIs) and β-blockers, and associated predictors, in senior patients after hospitalization for heart failure (HF). Methods: A population-based data set identified 4488 patients who survived 60 days following their index hospitalization for HF in Western Australia from 2003 to 2008 with a 3-year follow-up. Their person-linked Pharmaceutical Benefits Scheme records identified medications dispensed during follow-up. Drug discontinuation was defined as the first break ≥90 days following the previous supply. Medication adherence was calculated using the proportion of days covered (PDC), with PDC ≥ 80% defined as being adherent. Multivariable logistic regression models were used to identify predictors of PDC < 80%. Results: In the cohort (57% male, mean age: 76.6 years), 77.4% were dispensed a RASI and 52.7% a β-blocker within 60 days postdischarge. Over the 3-year follow-up, 28% and 42% of patients discontinued RASI and β-blockers, respectively. Only 64.6% and 47.5% of RASI and β-blocker users, respectively, were adherent to their treatment over 3 years, with adherence decreasing over time (trend P < .0001 for RASI and trend P = .02 for β-blockers). Older age, increasing Charlson comorbidity score, chronic kidney disease, and chronic obstructive pulmonary disease were independent predictors of PDC < 80% for both drug groups. Conclusion: Among seniors hospitalized for HF, discontinuation gaps were common for RASI and β-blockers postdischarge, and long-term adherence to these medications was suboptimal. Where appropriate, strategies to improve long-term medication adherence are indicated in HF patients, particularly in elderly patients with comorbidities.
APA, Harvard, Vancouver, ISO, and other styles
24

Rassi, Marcio S., and Ossama Al-Mefty. "Surgical Treatment of Bilateral Optic Nerve Sheath Meningioma: 2-Dimensional Operative Video." Operative Neurosurgery 20, no. 6 (May 3, 2021): E418—E419. http://dx.doi.org/10.1093/ons/opab052.

Full text
Abstract:
Abstract Even though intracranial meningiomas commonly invade the optic canals, true optic nerve sheath meningiomas are extremely rare. They are insidious lesions that frequently grow in 4 stages, leading to progressive visual loss.1–4 Frequently, management includes observation for asymptomatic patients, and fractioned stereotactic radiotherapy with progressive visual loss.1,3 However, surgery is avoided due to the risk of perioperative visual loss.2–4 However, many of these cases present in the early stage of tumor growth, where an arachnoidal plane is still present, and vision can be saved by microsurgical tumor resection.2 Here we present the case of a 33-yr-old female presenting with a 3-wk history of blurred vision. Neuroimaging depicted an enhancing lesion along both optic nerves consistent with bilateral optic nerve sheath meningioma. Neuroophthalmological examination showed inferior cut of visual field bilaterally, more extensive on the left eye. Acuity was 20/20 on both eyes. Microsurgical resection of the tumor was performed through left supraorbital craniotomy, with the goal of eliminating intracranial extension and stabilizing visual function.5 The optic canal was unroofed with diamond bit drill under copious irrigation. A remarkable improvement of her visual field was observed with maintenance of acuity at 20/20 on follow-up. As the patient is attempting pregnancy, she is closely monitored without radiation. Surgery can be offered as a primary treatment of optic nerve sheath meningiomas, especially in early stages, with likely preservation and, in some cases, improvement of visual function.6 The patient consented to the procedure and the use of image. Images at 1:46 and 3:48 reprinted from Al-Mefty O, Operative Atlas of Meningiomas. 1998: Raven Press; Philadelphia, PA, with permission from LWW. Image at 2:57 reprinted from Rassi et al2; © Anil Can, 2018, used with permission. Image at 9:27 in public domain/age.
APA, Harvard, Vancouver, ISO, and other styles
25

Toone, Eric J. "Carbohyrate Analysis: High Performance Liquid Chromatography and Capillary Electrophoresis Edited by Ziad El Rassi (Oklahoma State University). Elsevier: Amsterdam. 1995. xix + 668 pp. $242.75. ISBN 0-444-89981-2." Journal of the American Chemical Society 120, no. 1 (January 1998): 240. http://dx.doi.org/10.1021/ja955106m.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Manzi, A. E. "Journal of Chromatography Library, Volume 58, Carbohydrate Analysis: High-Performance Liquid Chromatography and Capillary Electrophoresis, Edited by Z. El Rassi, Elsevier Science, Amsterdam, The Netherlands, 1995, 672 pp., $265.75." Analytical Biochemistry 230, no. 2 (September 1995): 358. http://dx.doi.org/10.1006/abio.1995.1490.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Frank, Daniel. "Rashi." Journal of Jewish Studies 39, no. 2 (October 1, 1988): 283–84. http://dx.doi.org/10.18647/1420/jjs-1988.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Reif, Stefan C. "Rashi." Journal of Jewish Studies 64, no. 2 (October 1, 2013): 418–20. http://dx.doi.org/10.18647/3152/jjs-2013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Sherwood, Victoria, Asha Recino, Alex Jeffries, Andrew Ward, and Andrew D. Chalmers. "The N-terminal RASSF family: a new group of Ras-association-domaincontaining proteins, with emerging links to cancer formation." Biochemical Journal 425, no. 2 (December 23, 2009): 303–11. http://dx.doi.org/10.1042/bj20091318.

Full text
Abstract:
The RASSF (Ras-association domain family) has recently gained several new members and now contains ten proteins (RASSF1–10), several of which are potential tumour suppressors. The family can be split into two groups, the classical RASSF proteins (RASSF1–6) and the four recently added N-terminal RASSF proteins (RASSF7–10). The N-terminal RASSF proteins have a number of differences from the classical RASSF members and represent a newly defined set of potential Ras effectors. They have been linked to key biological processes, including cell death, proliferation, microtubule stability, promoter methylation, vesicle trafficking and response to hypoxia. Two members of the N-terminal RASSF family have also been highlighted as potential tumour suppressors. The present review will summarize what is known about the N-terminal RASSF proteins, addressing their function and possible links to cancer formation. It will also compare the N-terminal RASSF proteins with the classical RASSF proteins and ask whether the N-terminal RASSF proteins should be considered as genuine members or imposters in the RASSF family.
APA, Harvard, Vancouver, ISO, and other styles
30

Pfeifer, Gerd P., Reinhard Dammann, and Stella Tommasi. "RASSF proteins." Current Biology 20, no. 8 (April 2010): R344—R345. http://dx.doi.org/10.1016/j.cub.2010.02.019.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Kloner, Robert A., Coleman Gross, Jinwei Yuan, Ansgar Conrad, and Pablo E. Pergola. "Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors." Journal of Cardiovascular Pharmacology and Therapeutics 23, no. 6 (August 14, 2018): 524–31. http://dx.doi.org/10.1177/1074248418788334.

Full text
Abstract:
Introduction: Hyperkalemia (potassium >5.0 mEq/L) affects heart failure patients with renal disease regardless of the use of renin–angiotensin–aldosterone system inhibitors (RAASi). The open-label TOURMALINE study showed that patiromer, a sodium-free, nonabsorbed potassium binder, lowers serum potassium of hyperkalemic patients similarly when given with or without food; unlike prior studies, patients were not required to be taking RAASi. We conducted post hoc analyses to provide the first report of patiromer in patients not taking RAASi. Methods: Hyperkalemic patients received patiromer, 8.4 g/d to start, adjusted to achieve and maintain serum potassium of 3.8 to 5.0 mEq/L. If taking RAASi, stable doses were required. The primary end point was the proportion of patients with serum potassium 3.8 to 5.0 mEq/L at week 3 or 4. This analysis presents data by patients taking or not taking RAASi. Results: Demographics and baseline characteristics were similar in patients taking (n = 67) and not taking RAASi (n = 45). Baseline mean (SD) serum potassium was 5.37 (0.37) mEq/L and 5.42 (0.43) mEq/L in patients taking and not taking RAASi, respectively. Mean (SD) daily patiromer doses were similar (10.7 [3.2] and 11.5 [4.0] g, respectively). The primary end point was achieved in 85% (95% confidence interval [CI]: 74-93) of patients taking RAASi and in 84% (95% CI: 71-94) of patients not taking RAASi. From baseline to week 4, the mean (SE) change in serum potassium was −0.67 (0.08) mEq/L in patients taking RAASi and −0.56 (0.10) mEq/L in patients not taking RAASi (both P < .0001 vs baseline, P = nonsignificant between groups). Adverse events were reported in 26 (39%) patients taking RAASi and 25 (54%) not taking RAASi; the most common adverse event was diarrhea (2% and 11%, respectively; no cases were severe). Five patients (2 taking RAASi) reported 6 serious adverse events; none considered related to patiromer. Conclusions: Patiromer was effective and generally well-tolerated for hyperkalemia treatment, whether or not patients were taking RAAS inhibitors.
APA, Harvard, Vancouver, ISO, and other styles
32

Rosano, Giuseppe MC, Ilaria Spoletini, Cristiana Vitale, and Stefan Agewall. "Hyperkalemia and Renin–Angiotensin–Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction." Cardiac Failure Review 5, no. 3 (November 4, 2019): 130–32. http://dx.doi.org/10.15420/cfr.2019.8.2.

Full text
Abstract:
Renin–angiotensin–aldosterone system inhibitors (RAASi) are known to improve outcomes in patients who have heart failure with reduced ejection fraction (HFrEF). To reduce mortality in these patients, RAASi should be uptitrated to the maximally tolerated dose. However, RAASi may also cause hyperkalemia. As a result of this side-effect, doses of RAASi are reduced, discontinued and seldom reinstated. Thus, the therapeutic target needed in these patients is often not reached because of hyperkalemia. Also, submaximal dosing of RAASi may be a result of symptomatic hypotension, syncope, hypoperfusion, reduced kidney function and other factors. The reduction of RAASi dose leads to adverse outcomes, such as an increased risk of mortality. Management of these side-effects is pivotal to maximise the use of RAASi in HFrEF, particularly in high-risk patients.
APA, Harvard, Vancouver, ISO, and other styles
33

van den Belt, Sophie M., Hiddo J. L. Heerspink, Marietta Kirchner, Valentina Gracchi, Daniela Thurn-Valsassina, Aysun K. Bayazit, Anna Niemirska, et al. "Discontinuation of RAAS Inhibition in Children with Advanced CKD." Clinical Journal of the American Society of Nephrology 15, no. 5 (April 6, 2020): 625–32. http://dx.doi.org/10.2215/cjn.09750819.

Full text
Abstract:
Background and objectivesAlthough renin-angiotensin-aldosterone system inhibition (RAASi) is a cornerstone in the treatment of children with CKD, it is sometimes discontinued when kidney function declines. We studied the reasons of RAASi discontinuation and associations between RAASi discontinuation and important risk markers of CKD progression and on eGFR decline in the Cardiovascular Comorbidity in Children with CKD study.Design, setting, participants, & measurementsIn this study, 69 children with CKD (67% male, mean age 13.7 years, mean eGFR 27 ml/min per 1.73 m2) who discontinued RAASi during prospective follow-up were included. Initial change in BP, albuminuria, and potassium after discontinuation were assessed (median time 6 months). Rate of eGFR decline (eGFR slope) during a median of 1.9 years before and 1.2 years after discontinuation were estimated using linear mixed effects modeling.ResultsPhysician-reported reasons for RAASi discontinuation were increase in serum creatinine, hyperkalemia, and symptomatic hypotension. After discontinuation of RAASi, BP and albuminuria increased, whereas potassium decreased. eGFR declined more rapidly after discontinuation of RAASi (−3.9 ml/min per 1.73 m2 per year; 95% confidence interval, −5.1 to −2.6) compared with the slope during RAASi treatment (−1.5 ml/min per 1.73 m2 per year; 95% confidence interval, −2.4 to −0.6; P=0.005). In contrast, no change in eGFR slope was observed in a matched control cohort of patients in whom RAASi was continued.ConclusionsDiscontinuation of RAASi in children with CKD is associated with an acceleration of kidney function decline, even in advanced CKD.
APA, Harvard, Vancouver, ISO, and other styles
34

Hundemer, Gregory L., Robert Talarico, Navdeep Tangri, Silvia J. Leon, Sarah E. Bota, Emily Rhodes, Greg A. Knoll, and Manish M. Sood. "Ambulatory Treatments for RAAS Inhibitor–Related Hyperkalemia and the 1-Year Risk of Recurrence." Clinical Journal of the American Society of Nephrology 16, no. 3 (February 19, 2021): 365–73. http://dx.doi.org/10.2215/cjn.12990820.

Full text
Abstract:
Background and objectiveThe optimal ambulatory management of renin-angiotensin-aldosterone system inhibitor (RAASi)–related hyperkalemia to reduce the risk of recurrence is unknown. We examined the risk of hyperkalemia recurrence on the basis of outpatient pharmacologic changes following an episode of RAASi-related hyperkalemia.DesignWe performed a population-based, retrospective cohort study of older adults (n=49,571; mean age 79 years) who developed hyperkalemia (potassium ≥5.3 mEq/L) while on a RAASi and were grouped as follows: no intervention, RAASi discontinuation, RAASi dose decrease, new diuretic, diuretic dose increase, or sodium polystyrene sulfonate within 30 days. The primary outcome was hyperkalemia recurrence, with secondary outcomes of cardiovascular events and all-cause mortality within 1 year.ResultsAmong patients who received a pharmacologic intervention (23% of the cohort), RAASi discontinuation was the most commonly prescribed strategy (74%), followed by RAASi decrease (15%), diuretic increase (7%), new diuretic (3%), and sodium polystyrene sulfonate (1%). A total of 16,977 (34%) recurrent hyperkalemia events occurred within 1 year. Compared with no intervention (35%, referent), the cumulative incidence of recurrent hyperkalemia was lower with RAASi discontinuation (29%; hazard ratio, 0.82; 95% confidence interval, 0.78 to 0.85), whereas there was no difference with RAASi dose decrease (36%; hazard ratio, 0.94; 95% confidence interval, 0.86 to 1.02), new diuretic (32%; hazard ratio, 0.95; 95% confidence interval, 0.78 to 1.17), or diuretic increase (38%; hazard ratio, 0.99; 95% confidence interval, 0.87 to 1.12) and a higher incidence with sodium polystyrene sulfonate (55%; hazard ratio, 1.30; 95% confidence interval, 1.04 to 1.63). RAASi discontinuation was not associated with a higher risk of 1-year cardiovascular events (hazard ratio, 0.96; 95% confidence interval, 0.91 to 1.02) or all-cause mortality (hazard ratio, 1.05; 95% confidence interval, 0.96 to 1.15) compared with no intervention.ConclusionsAmong older adults with RAASi-related hyperkalemia, RAASi discontinuation is associated with the lowest risk of recurrent hyperkalemia, with no apparent increase in short-term risks for cardiovascular events or all-cause mortality.
APA, Harvard, Vancouver, ISO, and other styles
35

Hakiki, Falhan, and Deasy Silvya Sari. "Keterlibatan RAMSI (Regional Assistance Mission to Solomon Islands) dalam Penanggulangan Konflik di Kepulauan Solomon." Padjadjaran Journal of International Relations 2, no. 2 (September 30, 2020): 208. http://dx.doi.org/10.24198/padjir.v2i2.27263.

Full text
Abstract:
Konflik internal pada Kepulauan Solomon mengakibatkan terjadinya krisis kemanusiaan yang berdampak kepada terancamnya keamanan manusia masyarakat negara tersebut. Hal ini di respon oleh negara-negara di kawasan Pasifik untuk menanggulangi konflik dengan membentuk RAMSI (Regional Assistance Mission to Solomon Islands). Dengan menggunakan metode riset kualitatif dan kerangka konseptual keamanan non tradisional, keamanan manusia, dan tanggung jawab untuk melindungi, pada artikel ini di dapatkan peran RAMSI dalam menanggulangi konflik di Kepulauan Solomon ada tiga bentuk. Pertama, tanggung jawab untuk mencegah yaitu RAMSI melakukan intervensi dan stabilisasi. Kedua, tanggung jawab untuk bereaksi yaitu RAMSI melakukan serangkaian aksi seperti penyitaan senjata kelompok yang berkonflik, mengejar tokoh-tokoh kriminal dan korup, serta melakukan penegakkan hukum. Ketiga, tanggung jawab untuk pemulihan yaitu RAMSI melakukan pembangunan kapasitas di bidang hukum, politik, keamanan, ekonomi di Kepulauan Solomon.Kata Kunci: Keamanan Manusia, Kepulauan Solomon, Konflik, RAMSI, Tanggung Jawab untuk Melindungi
APA, Harvard, Vancouver, ISO, and other styles
36

Boas, Franz. "Rasse und Kultur." Zeitschrift für Kulturphilosophie 2012, no. 2 (2012): 377–90. http://dx.doi.org/10.28937/1000107471.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Clark, Geoffrey J., Shairaz Baksh, Farida Latif, and Dae-Sik Lim. "RASSF Family Proteins." Molecular Biology International 2012 (December 10, 2012): 1–2. http://dx.doi.org/10.1155/2012/938916.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Töppel, Roman. "„Volk und Rasse“." Vierteljahrshefte für Zeitgeschichte 64, no. 1 (January 15, 2016): 1–36. http://dx.doi.org/10.1515/vfzg-2016-0001.

Full text
Abstract:
Vorspann Er ist wieder da - aber woher kam Hitler und aus welchen Quellen schöpfte er bei der Niederschrift von „Mein Kampf“. Roman Töppel, einer der Herausgeber der gerade vorgelegten Edition, geht dieser Frage mit Blick auf das ideologische Kernkapitel „Volk und Rasse“ nach, in dem Hitler die Figur „des Juden“ als Feindbild und Antityp des „rassereinen Ariers“ aufbaute. Seine intellektuellen Stichwortgeber waren dabei, so Töppel nach beeindruckend umsichtiger Recherche, vor allem Houston Stewart Chamberlain, Heinrich Claß, Theodor Fritsch, Dietrich Eckart, Hans F.K. Günther und Alfred Rosenberg, wobei Hitler aber selbst bei seinen bevorzugten Gewährsleuten alles ignorierte, was nicht in sein bereits relativ gefestigtes Weltbild passte.
APA, Harvard, Vancouver, ISO, and other styles
39

Wang, Angela Yee-Moon. "Optimally managing hyperkalemia in patients with cardiorenal syndrome." Nephrology Dialysis Transplantation 34, Supplement_3 (December 1, 2019): iii36—iii44. http://dx.doi.org/10.1093/ndt/gfz225.

Full text
Abstract:
Abstract Renin–angiotensin–aldosterone system inhibitors (RAASi) are now a standard treatment in most patients with cardiovascular disease, especially in those with heart failure (HF). The European Society of Cardiology and the American College of Cardiology/American Heart Association gave a Class IA recommendation for the use of RAASi in the treatment of Classes II–IV symptomatic HF with reduced ejection fraction (HFREF), based on their strong clinical benefits of lowering all-cause mortality and HF hospitalizations in these subjects. However, RAASi therapy or adding mineralocorticoid receptor antagonists in subjects receiving background angiotensin-converting enzyme inhibitors or angiotensin receptor blockers may be associated with an increased risk of hyperkalemia (HK), especially in those with reduced kidney function. As a result, a significant proportion of these subjects either have RAASi dose reduced or more often discontinued when they develop HK. Discontinuation of RAASi in patients hospitalized with HFREF was associated with higher postdischarge mortality and rehospitalization rates, while optimal dosing of RAASi significantly reduced median hospital stays, outpatient visits and related costs. Thus, effective treatment is required to lower potassium level and maintain normokalemia in subjects with HF and reduced kidney disease who develop or are at risk of HK, thus enabling them to continue their RAASi therapy and maximize benefits from RAASi. In this review, we provide an up-to-date review of the prevalence and significance of HK in patients with cardiorenal syndrome, as well as their optimal management of HK with recent novel therapies.
APA, Harvard, Vancouver, ISO, and other styles
40

Chiang, Cho Hung, Cho Han Chiang, YUANPING HSIA, Cho Hsien Chiang, and Her-Shyong Shiah. "The impact of renin-angiotensin-aldosterone system inhibitors on immune checkpoint inhibitor-associated adverse cardiovascular events." Journal of Clinical Oncology 41, no. 16_suppl (June 1, 2023): 2605. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.2605.

Full text
Abstract:
2605 Background: Immune checkpoint inhibitors (ICIs) are associated with adverse cardiovascular events that impair patient outcomes. Previous observational studies showed that renin-angiotensin-aldosterone system inhibitors (RAASi) may mitigate the cardiotoxicity associated with chemotherapeutic agents. However, the effects of RAASi on ICI-associated adverse cardiovascular events are unknown. Methods: We conducted a 1:1 propensity score-matched cohort study involving ICI-treated patients at two tertiary referral centers in Taiwan. The propensity score matching model includes age, sex, hypertension, diabetes mellitus, chronic kidney disease, Eastern Cooperative Oncology Group (ECOG) Performance Scale, cancer stage, and cancer type. The primary outcome was major adverse cardiovascular events (MACE), defined as a composite of myocardial infarction (MI), ischemic stroke, peripheral arterial occlusive disease (PAOD), pulmonary embolism (PE), deep venous thrombosis (DVT), heart failure, pericardial disease, myocarditis, and cardiac arrhythmias. The secondary outcomes were arterial thrombotic events (MI, ischemic stroke, PAOD) and venous thrombotic events (PE and DVT). Results: We identified 684 patients eligible for inclusion, from which 164 patients who received RAASi were matched to patients who did not receive RAASi. Over a median follow-up of 9.1 months, the incidence rate of MACE for RAASi and non-RAASi recipients was 6.5 and 13.9 per 100 patient-years, respectively, resulting in an incidence rate ratio of 0.47 [95% CI: 0.21–1.00] (p = 0.038). In a multivariate Cox proportional hazard model adjusting for cancer therapy, RAASi recipients had an approximately 60% reduction in the risk for MACE (HR, 0.37 [95% CI: 0.16-0.86], p = 0.021). In the secondary analysis, RAASi were associated with a reduction in venous thrombotic events (HR, 0.11 [95% CI: 0.02-0.63], p = 0.013), but not for arterial thrombotic events (HR, 0.47 [95% CI: 0.06-3.38], p = 0.45). Conclusions: In patients receiving ICI therapy, the use of RAASi is associated with a decreased cardiovascular risk, particularly for venous thrombotic events. [Table: see text]
APA, Harvard, Vancouver, ISO, and other styles
41

Silva-Cardoso, José, Dulce Brito, João Miguel Frazão, Aníbal Ferreira, Paulo Bettencourt, Patrícia Branco, and Cândida Fonseca. "Management of RAASi-associated hyperkalemia in patients with cardiovascular disease." Heart Failure Reviews 26, no. 4 (February 18, 2021): 891–96. http://dx.doi.org/10.1007/s10741-020-10069-3.

Full text
Abstract:
AbstractRenin–angiotensin–aldosterone system inhibitors (RAASi) reduce morbidity and mortality in heart failure (HF) with reduced ejection fraction in a dose-dependent manner. They also have a positive impact in other cardiovascular diseases (CVDs). However, RAASi may induce hyperkalemia, a potentially life-threatening disorder. This risk is further increased in those with concomitant chronic kidney disease, diabetes mellitus, and/or in patients with hypertension. Current treatment guidelines recommend maximal RAASi dosing to improve clinical outcomes; however, this is often limited by the development of hyperkalemia. When this occurs, current guidelines recommend RAASi down-titration/interruption, which, while improving short-term prognosis, is associated with a negative long-term prognostic impact. At present, the European Society of Cardiology suggests the consideration of novel potassium binders (patiromer and sodium zirconium cyclosilicate) for the management of RAASi-associated hyperkalemia. Both drugs can reduce serum potassium levels and prevent recurrent hyperkalemia. Additionally, patiromer showed enabling of RAASi optimization in high-risk patients. Nevertheless, precise recommendations on the use of these drugs are lacking. Building upon current HF guideline recommendations, a multidisciplinary expert panel convened to design an algorithm providing practical guidance on the use of novel potassium binders/patiromer in patients with HF and/or other CVD. As a result of that effort, we present an evidence-based treatment algorithm for the management of hyperkalemia with novel potassium binders/patiromer in patients with HF and/or other CVD receiving RAASi, including the necessary monitoring to avoid induction of hypokalemia. This algorithm aims to maintain or up-titrate RAASi to optimized doses, while maintaining normokalemia, improved clinical outcomes, and long-term prognosis.
APA, Harvard, Vancouver, ISO, and other styles
42

Žižović, Mališa, Dragan Pamučar, Miloljub Albijanić, Prasenjit Chatterjee, and Ivan Pribićević. "Eliminating Rank Reversal Problem Using a New Multi-Attribute Model—The RAFSI Method." Mathematics 8, no. 6 (June 21, 2020): 1015. http://dx.doi.org/10.3390/math8061015.

Full text
Abstract:
Multi-attribute decision-making (MADM) methods represent reliable ways to solve real-world problems for various applications by providing rational and logical solutions. In reaching such a goal, it is expected that MADM methods would eliminate inconsistencies like rank reversal issues in a given solution. In this paper, an endeavor is taken to put forward a new MADM method, called RAFSI (Ranking of Alternatives through Functional mapping of criterion sub-intervals into a Single Interval), which successfully eliminates the rank reversal problem. The developed RAFSI method has three major advantages that recommend it for further use: (i) its simple algorithm helps in solving complex real-world problems, (ii) RAFSI method has a new approach for data normalization, which transfers data from the starting decision-making matrix into any interval, suitable for making rational decisions, (iii) mathematical formulation of RAFSI method eliminates the rank reversal problem, which is one of the most significant shortcomings of existing MADM methods. A real-time case study that shows the advantages of RAFSI method is presented. Additional comprehensive analysis, including a comparison with other three traditional MADM methods that use different ways for data normalization and testing the resistance of RAFSI method and other MADM methods to rank the reversal problem, is also carried out.
APA, Harvard, Vancouver, ISO, and other styles
43

Gultom, Andri Fransiskus. "BAHASA RASIS PEMIMPIN PERGURUAN TINGGI DALAM PARADIGMA HISTORIS EDDIE COLE." Metahumaniora 12, no. 2 (September 12, 2022): 181. http://dx.doi.org/10.24198/metahumaniora.v12i2.38682.

Full text
Abstract:
Penelitian ini bertujuan untuk mengungkap bahasa rasis dalam lingkup akademis. Bahasa rasis ditemukan dalam ungkapan atau ujaran dari para pemimpin perguruan tinggi untuk mendiskriminasi ras kulit hitam. Penelitian menggunakan metode kualitatif dengan paradigma historis resistensi di kampus-kampus di Amerika Serikat. Beberapa metode yang digunakan: verstehen atau pembacaan teks dengan memahami terlebih dahulu data primer. deksripsi komparatif pada isu rasisme dalam konteks Indonesia. Untuk itu, penulis juga melakukan interpretasi yakni menafsirkan problem bahasa rasis dengan memahami situasi akademis di Indonesia dan memberi solusi. Temuan penelitian yaitu pertama, pemimpin perguruan tinggi adalah administrator pengambil kebijakan penting yang diharapkan untuk berbicara kepada publik ketika rasisme terjadi di kampus-kampus, namun sebagian dari mereka menyampaikan ujaran rasis. Kedua, bahasa rasis terungkap secara implisit dan eksplisit di universitas dalam beragam kebijakan, mulai dari saat pendaftaran, diskriminasi perumahan mahasiswa kulit hitam, sistem birokrasi perguruan tinggi yang berubah, konflik administrasi kampus, segregrasi, kekerasan di kampus dan problem hak-hak sipil. Rekomendasi penelitian bahwa affirmative action perlu dijalankan dalam bentuk komunikasi dan transformasi di perguruan tinggi.
APA, Harvard, Vancouver, ISO, and other styles
44

Scrace, Simon F., and Eric O'Neill. "RASSF Signalling and DNA Damage: Monitoring the Integrity of the Genome?" Molecular Biology International 2012 (April 11, 2012): 1–11. http://dx.doi.org/10.1155/2012/141732.

Full text
Abstract:
The RASSF family of proteins has been extensively studied in terms of their genetics, structure and function. One of the functions that has been increasingly studied is the role of the RASSF proteins in the DNA damage response. Surprisingly, this research, which encompasses both the classical and N-terminal RASSF proteins, has revealed an involvement of the RASSFs in oncogenic pathways as well as the more familiar tumour suppressor pathways usually associated with the RASSF family members. The most studied protein with respect to DNA damage is RASSF1A, which has been shown, not only to be activated by ATM, a major regulator of the DNA damage response, but also to bind to and activate a number of different pathways which all lead to and feedback from the guardian of the genome, p53. In this review we discuss the latest research linking the RASSF proteins to DNA damage signalling and maintenance of genomic integrity and look at how this knowledge is being utilised in the clinic to enhance the effectiveness of traditional cancer therapies such as radiotherapy.
APA, Harvard, Vancouver, ISO, and other styles
45

Boček, Petr. "Carbohydrate analysis: High performance liquid chromatography and capillary electrophoresis. Ziad El Rassi (Ed.), Elsevier, Amsterdam-Lausanne-New York-Oxford-Shannon-Tokyo, 1995, pp. 1-672, J. Chromatogr. Library, Volume 58, ISBN 0-444-89981-2, Price: Dfl 425.00, US$ 242.75." Electrophoresis 16, no. 1 (1995): 2172. http://dx.doi.org/10.1002/elps.11501601350.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Keller, Erich. "Das Herauskristallisieren der Rasse." Historische Anthropologie 14, no. 1 (January 2006): 49–67. http://dx.doi.org/10.7788/ha.2006.14.1.49.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Geulen, Christian. ",Rasse‘, Rassismus und Antirassismus." Recht und Politik 56, no. 3 (July 1, 2020): 252–57. http://dx.doi.org/10.3790/rup.56.3.252.

Full text
Abstract:
Wie hängen der Begriff ‚Rasse‘ und das Phänomen Rassismus zusammen? Gibt es nur dort Rassismus, wo auch von ‚Rassen‘ die Rede ist? Können wir also Rassismus bekämpfen, in dem wir den Begriff der ‚Rasse‘ tilgen? Oder hat sich der Rassismus längst von diesem Begriff gelöst? Das sind Fragen, die es wohl zu diskutieren gilt, bevor in bester Absicht das Grundgesetz geändert wird.
APA, Harvard, Vancouver, ISO, and other styles
48

Touati, Charles. "Rashi commentateur du Talmud." Comptes-rendus des séances de l année - Académie des inscriptions et belles-lettres 134, no. 3 (1990): 604–7. http://dx.doi.org/10.3406/crai.1990.14881.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Kischel, Uwe. "Rasse, Rassismus und Grundgesetz." Archiv des öffentlichen Rechts 145, no. 2 (2020): 227. http://dx.doi.org/10.1628/aoer-2020-0011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Polianski, Igor J. "Handschrift, Minderwertigkeit und Rasse." Medizinhistorisches Journal 54, no. 2 (2019): 108. http://dx.doi.org/10.25162/mhj-2019-0004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'RASSI' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography